BioAtla to Announce First Quarter 2025 Financial Results and Provide Business Highlights on May 6, 2025
BioAtla, a global clinical-stage biotechnology company, has scheduled its first quarter 2025 financial results announcement and business highlights conference call for May 6, 2025, at 4:30 p.m. ET.
The company, which specializes in developing Conditionally Active Biologic (CAB) antibody therapeutics for solid tumor treatment, will host both a conference call and webcast. Investors and interested parties can access the event through:
- Domestic dial-in: (800) 245-3047
- International dial-in: (203) 518-9765
- Conference ID: BIOATLA
Financial results will be available before the conference call via the "News Releases" section on BioAtla's website. A replay of the presentation will be accessible through the "Events & Presentations" section in the Investors area of the company website.
BioAtla, un'azienda biotecnologica globale in fase clinica, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 e la conferenza sui principali aggiornamenti aziendali per il 6 maggio 2025 alle 16:30 ET.
L'azienda, specializzata nello sviluppo di anticorpi terapeutici biologici condizionatamente attivi (CAB) per il trattamento dei tumori solidi, terrà sia una conference call che una webcast. Investitori e parti interessate possono partecipare all'evento tramite:
- Numero nazionale: (800) 245-3047
- Numero internazionale: (203) 518-9765
- ID conferenza: BIOATLA
I risultati finanziari saranno disponibili prima della conference call nella sezione "Comunicati Stampa" del sito web di BioAtla. Una registrazione della presentazione sarà accessibile nella sezione "Eventi e Presentazioni" nell'area Investitori del sito aziendale.
BioAtla, una empresa biotecnológica global en etapa clínica, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 y la conferencia sobre aspectos destacados del negocio para el 6 de mayo de 2025 a las 4:30 p.m. ET.
La compañía, especializada en el desarrollo de anticuerpos terapéuticos biológicos condicionalmente activos (CAB) para el tratamiento de tumores sólidos, realizará una llamada de conferencia y una transmisión web. Inversionistas y partes interesadas pueden acceder al evento a través de:
- Marcación nacional: (800) 245-3047
- Marcación internacional: (203) 518-9765
- ID de la conferencia: BIOATLA
Los resultados financieros estarán disponibles antes de la llamada de conferencia en la sección "Comunicados de prensa" del sitio web de BioAtla. Una repetición de la presentación estará accesible en la sección "Eventos y Presentaciones" en el área de Inversionistas del sitio web de la empresa.
BioAtla는 글로벌 임상 단계 생명공학 회사로, 2025년 1분기 재무 결과 발표 및 사업 주요 사항 컨퍼런스 콜을 2025년 5월 6일 오후 4시 30분(동부 시간)에 예정하고 있습니다.
고형 종양 치료를 위한 조건부 활성 생물학적(CAB) 항체 치료제 개발을 전문으로 하는 이 회사는 컨퍼런스 콜과 웹캐스트를 모두 진행할 예정입니다. 투자자 및 관심 있는 분들은 다음을 통해 행사에 참여할 수 있습니다:
- 국내 전화 접속: (800) 245-3047
- 국제 전화 접속: (203) 518-9765
- 컨퍼런스 ID: BIOATLA
재무 결과는 컨퍼런스 콜 전에 BioAtla 웹사이트의 "뉴스 릴리스" 섹션에서 확인할 수 있습니다. 발표 녹화는 회사 웹사이트 투자자 섹션 내 "이벤트 및 발표"에서 다시보기로 제공됩니다.
BioAtla, une société biotechnologique mondiale en phase clinique, a programmé l'annonce de ses résultats financiers du premier trimestre 2025 et une conférence téléphonique sur les faits marquants de l'entreprise le 6 mai 2025 à 16h30 heure de l'Est.
Spécialisée dans le développement de thérapeutiques à base d'anticorps biologiques conditionnellement actifs (CAB) pour le traitement des tumeurs solides, la société organisera une conférence téléphonique et une webdiffusion. Les investisseurs et parties intéressées peuvent accéder à l'événement via :
- Numéro national : (800) 245-3047
- Numéro international : (203) 518-9765
- ID de la conférence : BIOATLA
Les résultats financiers seront disponibles avant la conférence téléphonique dans la section « Communiqués de presse » du site web de BioAtla. Une rediffusion de la présentation sera accessible dans la section « Événements & Présentations » de l’espace Investisseurs du site de la société.
BioAtla, ein globales biotechnologisches Unternehmen in der klinischen Phase, hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 sowie eine Telefonkonferenz zu den Geschäftshighlights für den 6. Mai 2025 um 16:30 Uhr ET geplant.
Das Unternehmen, das sich auf die Entwicklung von bedingt aktiven biologischen (CAB) Antikörpertherapeutika zur Behandlung solider Tumoren spezialisiert hat, wird sowohl eine Telefonkonferenz als auch eine Webcast veranstalten. Investoren und Interessierte können über folgende Zugänge teilnehmen:
- Inländische Einwahl: (800) 245-3047
- Internationale Einwahl: (203) 518-9765
- Konferenz-ID: BIOATLA
Die Finanzergebnisse werden vor der Telefonkonferenz im Bereich "Pressemitteilungen" auf der BioAtla-Website verfügbar sein. Eine Aufzeichnung der Präsentation wird im Bereich "Veranstaltungen & Präsentationen" für Investoren auf der Unternehmenswebseite abrufbar sein.
- Clinical-stage biotech company with focus on CAB antibody therapeutics for solid tumors, indicating specialized market positioning
- None.
SAN DIEGO, April 29, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2025 and provide business highlights.
Conference Call and Webcast Information
Date: Tuesday, May 6, 2025
Time: 4:30 p.m. ET
Webcast Link: BioAtla First Quarter 2025 Earnings Conference Call
Dial-in Numbers: (800) 245-3047 (domestic), (203) 518-9765 (international)
Conference ID: BIOATLA
The press release with the financial results will be accessible prior to the conference call through “News Releases” in the News & Events section of the company’s website. A replay of the call will also be available through “Events & Presentations” in the Investors section of the company’s website.
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through its contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary CAB platform technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB platform technology and products with greater than 780 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. The Company also has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
When will BioAtla (BCAB) release Q1 2025 earnings?
How can investors join BioAtla's Q1 2025 earnings call?
What is BioAtla's (BCAB) main business focus?
Where can investors find BioAtla's Q1 2025 financial results?
